Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Lambda in COVID-19
NCT04343976Phase 2
Key facts
- Status
- Terminated
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Countries
- 1
- Modality
- Cytokines & Interferons
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Lambda Treatment with Saline Placebo (2 arms). Primary endpoint: Undetectable COVID PCR at Day 7. Started Jun 2020; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Lambda Treatment
Pegylated Interferon Lambda
Saline Placebo
Saline Placebo
03
Who it enrols
Adult patients with confirmed COVID-19 diagnosis within 48 hours of randomization, excluding those with severe respiratory compromise requiring ventilation (other than nasal cannula) or significant lab abnormalities.
04
Endpoints
Primary
Undetectable COVID PCR at Day 7
Secondary
Undetectable COVID PCR at Day 3
Percentage of Subjects on Lambda vs Placebo With Symptomatic Improvement
Percentage of Subjects on Lambda vs Placebo With Improved Clinical Outcomes
Undetectable COVID PCR Testing at Day 14
Beyond the preview
Go deeper on NCT04343976.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343976.